argenx (ARGX) Reports ADDRESS Study of Efgartigimod SC Did Not Achieve Statistical Significance

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 7/2/2026

1. NKE
2. TSLA
3. MU
4. SPY
5. NVDA
6. BE
7. SPCX
8. STZ
9. META
10. ABVX

Go back to argenx (ARGX) Reports ADDRESS Study of Efgartigimod SC Did Not Achieve Statistical Significance

argenx Reports Topline Results from ADDRESS Study of Efgartigimod SC in Pemphigus

December 20, 2023 1:00 AM EST

ADDRESS study did not meet primary or secondary endpoints Pemphigus deprioritized as efgartigimod indicationUpdate on BALLAD study GO/NO GO decisionConference call scheduled for today, December 20, 2023, at 8:30am ET (2:30pm CET)

Regulated Information Inside Information

December 20, 2023, 7:00am CET

... More